Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07461948 · ClinicalTrials.gov registry record · Phase 3
Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
A Phase 3 study of Glioblastoma, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT07461948 is a Phase 3 study of Glioblastoma that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 15 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07461948, a Phase 3 study of Glioblastoma, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase III trial is evaluating whether a combination of three advanced magnetic resonance imaging (MRI) techniques, including chemical exchange saturation transfer (CEST) MRI, diffusion-relaxation correlation spectrum imaging (DR-CSI), and ferumoxytol-enhanced magnetic resonance imaging (Fe-MRI) are effective as non-invasive methods for assessing the cells and proteins that surround and interact with tumor cells (the tumor immune microenvironment) in patients with glioblastoma. Researchers understand that some types of brain tumors are harder to treat than others, but the reasons for this are not known in many cases. CEST MRI uses differences in the tissue microenvironment, like protein concentration or intracellular pH, to generate contrast differences. DR-CSI detects microstructural changes in tissue associated with immune cells infiltrating the tumor. Fe-MRI uses ferumoxytol as a contrast agent with MRI. Contrast agents are substances that are injected into the body and taken up by certain tissues, making the tissues easier to see in imaging scans. More advanced imaging techniques like CEST, DR-CSI, and Fe-MRI may offer less invasive methods than surgery or biopsy for helping researchers understand the tumor immune microenvironment in patients with glioblastoma, which may help researchers determine why some tumors are more resistant to treatment.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- DRUG Ferumoxytol
- OTHER Electronic Health Record Review
- PROCEDURE Chemical Exchange Saturation Transfer Magnetic Resonance Imaging
- PROCEDURE Diffusion-Relaxation Correlation Spectrum Imaging
Study Locations (1)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-10-27 |
| Est. Completion | 2028-10-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07461948
The ClinicalTrials.gov registry entry for NCT07461948 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (86% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07461948 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07461948 about?
NCT07461948 is a clinical study titled "Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients". This phase III trial is evaluating whether a combination of three advanced magnetic resonance imaging (MRI) techniques, including chemical exchange saturation transfer (CEST) MRI, diffusion-relaxation correlation spectrum imaging (DR-CSI), and ferumoxytol-enhanced magnetic resonance imaging (Fe-MRI)...
What is the current status of trial NCT07461948?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2025-10-27. Estimated completion is 2028-10-27.
What conditions does trial NCT07461948 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT07461948?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Ferumoxytol (DRUG), Electronic Health Record Review (OTHER), Chemical Exchange Saturation Transfer Magnetic Resonance Imaging (PROCEDURE), Diffusion-Relaxation Correlation Spectrum Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT07461948?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07461948 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
RECRUITING · Phase 3
-
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
RECRUITING · Phase 3
-
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
RECRUITING · Phase 3
-
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
RECRUITING · Phase 3
-
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
ACTIVE NOT RECRUITING · Phase 3
-
Tofacitinib in Recurrent GBM Patients
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.